Medeon Biodesign, Inc. (TPEX:6499)

Taiwan · Delayed Price · Currency is TWD

73.70

+0.50 (0.68%)

Jun 18, 2026, 1:30 PM CST

-45.20% (1Y)

Market Cap	7.14B -34.0%
Revenue (ttm)	431.84M +24.3%
Net Income	-611.93M
EPS	-6.55
Shares Out	96.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,697
Open	73.50
Previous Close	73.20
Day's Range	72.20 - 74.30
52-Week Range	72.00 - 154.50
Beta	0.56
Analysts	Strong Buy
Price Target	200.00 (+171.37%)
Earnings Date	May 8, 2026

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to pr... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2012

Employees 39

Stock Exchange Taipei Exchange

Ticker Symbol 6499

Full Company Profile

Financial Performance

In 2025, Medeon Biodesign's revenue was 419.43 million, an increase of 43.24% compared to the previous year's 292.81 million. Losses were -668.06 million, -17.06% less than in 2024.

Financial Statements